NeuroVive and to-BBB to jointly develop therapy for stroke
(Thomson Reuters ONE) -
Lund, Sweden / Leiden, the Netherlands, 25(th) October 2010
NeuroVive Pharmaceutical and to-BBB, the Dutch drug brain delivery company, are
entering into a joint program to develop therapies for stroke and other acute
neurodegenerative diseases by combining their technologies.
NeuroVive Pharmaceutical is engaged in research and development of nerve cell-
protecting and regenerative cyclosporin-based pharmaceuticals for the treatment
of traumatic brain injuries (TBI) and other neurological diseases. The Company's
first product NeuroSTAT®, is a novel, cremophor-free, cyclosporin-A lipid
emulsion.
"The collaboration with to-BBB opens up the possibility of treating brain
disorders beyond TBI. There is a tremendous unmet medical need in treating
patients with acute neurodegeneration such as stroke, cardiac-arrest-induced
brain damage and spinal cord injuries, where one can expect the blood-brain
barrier (BBB) to significantly prevent drug penetration to the central nervous
system (CNS)", says Dr Eskil Elmér, CSO of NeuroVive.
Pieter Gaillard, CSO of to-BBB, adds: "The BBB is indeed a significant obstacle
in the treatment of CNS disorders. to-BBB's proprietary G-Technology(®) can
safely enhance drug delivery to the brain and we are excited to address this
with NeuroVive's cyclosporin-based pharmaceuticals".
"Currently there are no approved pharmacological or cellular primary
neuroprotective treatments for stroke and spinal cord injuries. Consequently,
the need to develop treatment for acute degenerative disorders has never been
greater than it is today. The deal with to-BBB has the potential to generate
drugs for large markets in CNS diseases such as stroke", says Mikael Brönnegård,
CEO of NeuroVive.
"We are very pleased to collaborate with NeuroVive," says Willem van Weperen,
CEO of to-BBB. We are convinced that synergies in research and clinical
platforms as well as business and commercial strategies between to-BBB and
NeuroVive will result in a very strong partnership that will benefit patients
with these devastating CNS diseases".
NeuroVive is funding the initial development up to preclinical Proof of Concept,
after which the two companies have agreed to develop and commercialize the
product jointly.
About NeuroVive
NeuroVive Pharmaceutical AB is a Swedish drug development company. NeuroVive's
primary mission is to develop drugs which protect nerve cells. The company is
currently conducting clinical trials with NeuroSTAT®. In addition to introducing
NeuroSTAT® as the first cyclophilin-D-inhibiting mitochondrial protectant,
NeuroVive is researching and developing variants of cyclophilin-inhibiting
cyclosporins and new ways of transporting these drugs across the blood-brain
barrier to the central nervous system. NeuroVive Pharmaceutical AB (publ) shares
are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The
AktieTorget market is focused on emerging, entrepreneurial businesses and offers
an electronic trading system supplied by the OMX Nordic stock exchange in
Stockholm, Sweden.
About to-BBB
to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery
across the blood-brain barrier. The company is developing novel treatments for
brain disorders by combining existing drugs with its proprietary brain drug
delivery platform. The company's vision is that the treatment of currently
unserved brain diseases will be best achieved by safely enhancing the blood-to-
brain delivery of drugs.
to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and
established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.
Contact
Mikael Brönnegård, MD., PhD, Eskil Elmér, MD., PhD,
Chief Executive Officer Chief Scientific Officer
Phone: +46 46 2880110 Phone: +46 46 2880110
Mobile: +46 702996264 Mobile: +46 733919601
E-mail: mikael.bronnegard(at)neurovive.com Email: eskil.elmer(at)neurovive.com
NeuroVive Pharmaceutical AB (publ) NeuroVive Pharmaceutical AB (publ)
Biomedical Center BMC D10 Biomedical Center BMC D10
221 84 Lund, Sweden 221 84 Lund, Sweden
www.neurovive.com www.neurovive.com
Willem van Weperen, MSc, MBA Pieter Gaillard, PhD
Chief Executive Officer Chief Scientific Officer
Phone: +31 71 3322252 Phone: +31 71 3322251
Mobile: +31 634 054812 Mobile: +31 621 525000
E-mail: vanweperen(at)toBBB.com E-mail: gaillard(at)toBBB.com
to-BBB technologies BV to-BBB technologies BV
Niels Bohrweg 11, 2333 CA Leiden Niels Bohrweg 11, 2333 CA Leiden
BioScience Park Leiden BioScience Park Leiden
Bio Partner Center II Bio Partner Center II
The Netherlands The Netherlands
www.toBBB.com www.toBBB.com
[HUG#1454727]
Press Release (PDF):
http://hugin.info/139945/R/1454727/394880.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NeuroVive Pharmaceutical AB via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 25.10.2010 - 07:00 Uhr
Sprache: Deutsch
News-ID 46088
Anzahl Zeichen: 0
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NeuroVive and to-BBB to jointly develop therapy for stroke"
steht unter der journalistisch-redaktionellen Verantwortung von
NeuroVive Pharmaceutical AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
